Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV003362661 | SCV004084527 | likely pathogenic | Inborn genetic diseases | 2023-08-21 | criteria provided, single submitter | clinical testing | The c.2689G>A (p.E897K) alteration is located in exon 13 (coding exon 13) of the TRPC6 gene. This alteration results from a G to A substitution at nucleotide position 2689, causing the glutamic acid (E) at amino acid position 897 to be replaced by a lysine (K). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This variant has been identified in multiple individuals with clinical features consistent with TRPC6-related focal segmental glomerulosclerosis (Reiser, 2005; Groopman, 2019; Lu, 2022). This amino acid position is highly conserved in available vertebrate species. Based on internal structural analysis, E897K is more disruptive to the CH2 domain of TRPC6 than our internal threshold for deleterious destabilization, though there are no comparable internally pathogenic variants nearby for comparison (Tang, 2018; Guo, 2022). Functional studies show that E897K leads to altered protein function (Reiser, 2005; Riehle, 2016; Polat, 2019; Schlöndorff, 2009). This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as likely pathogenic. |
OMIM | RCV000006531 | SCV000026714 | pathogenic | Focal segmental glomerulosclerosis 2 | 2005-07-01 | no assertion criteria provided | literature only | |
Gharavi Laboratory, |
RCV000681807 | SCV000809278 | pathogenic | not provided | 2018-09-16 | no assertion criteria provided | research |